Oncotarget

Research Papers:

Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and meta-analysis

Li-Na Zhou, Yue Tan, Ping Li, Ping Zeng, Min-Bin Chen, Ye Tian and Ya-Qun Zhu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:303-314. https://doi.org/10.18632/oncotarget.13863

Metrics: PDF 2426 views  |   HTML 2874 views  |   ?  


Abstract

Li-Na Zhou1,2,*, Yue Tan1,2,*, Ping Li1,2,*, Ping Zeng2, Min-Bin Chen2, Ye Tian1, Ya-Qun Zhu1

1Department of Radiotherapy and Oncology, the Second Affiliated Hospital of Soochow University, Institute of Radiotherapy & Oncology, Soochow University, Suzhou, Jiangsu 215004, China

2Department of Radiotherapy and Oncology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu Province, China

*These authors have contributed equally to this work and should be considered co-first authors

Correspondence to:

Ya-Qun Zhu, email: [email protected]

Keywords: KPNA2, tumor, prognosis, overall survival

Received: July 04, 2016    Accepted: November 14, 2016    Published: December 10, 2016

ABSTRACT

Background: Karyopherin α2 (KPNA2), a member of the Karyopherin α family, has recently been reported to play an important role in tumor progression. However, the association between KPNA2 expression and prognosis in cancer remains controversial. So we performed this meta-analysis to evaluate whether expression of KPNA2 was associated with prognosis in patients with solid tumor.

Methods/Findings: 24 published eligible studies, including 6164 cases, were identified and included in this meta-analysis through searching of PubMed, EMBASE and Web of Science. We found that KPNA2 expression was an independent predictor for the prognosis of solid tumor with primary outcome (overall survival [OS]: pooled HR=1.767, 95% CI=1.503-2.077, P<0.001) and secondary outcomes (time to recurrence [TTR], recurrence free survival [RFS] and progression free survival [PFS]). However, the association between KPNA2 overexpression and disease free survival [DFS] in solid tumors was not significant (pooled HR=1.653, 95% CI=0.903-3.029, P=0.104). Furthermore, the subgroup analysis revealed that KPNA2 overexpression was associated with poor OS in East-Asian patients and European patients, as well as patients with gastric and colorectal cancer.

Conclusion: KPNA2 expression may be a useful prognostic biomarker to monitor cancer prognosis. Further prospective studies with larger sample sizes are required to confirm our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13863